The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment
- PMID: 28089821
- DOI: 10.1016/j.mce.2017.01.004
The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment
Abstract
Glioblastoma multiforme (GBM) is the most aggressive form of cancer that begins within the brain; generally, the patient has a dismal prognosis and limited therapeutic options. Signal transducer and activator of transcription 3 (STAT3) is a critical mediator of tumorigenesis, tumor progression, and suppression of anti-tumor immunity in GBM. In a high percentage of GBM cells and tumor microenvironments, persistent activation of STAT3 induces cell proliferation, anti-apoptosis, glioma stem cell maintenance, tumor invasion, angiogenesis, and immune evasion. This makes STAT3 an attractive therapeutic target and a prognostic indicator in GBM. Targeting STAT3 affords an opportunity to disrupt multiple pro-oncogenic pathways at a single molecular hub. Unfortunately, there are no successful STAT3 inhibitors currently in clinical trials. However, strong clinical evidence implicating STAT3 as a major factor in GBM justifies the identification of safe and effective strategies for inhibiting STAT3.
Keywords: Glioblastoma multiforme; Prognosis; Signal transducer and activator of transcription 3; Therapeutic target; Tumor microenvironment; Tumor progression.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Potential role for STAT3 inhibitors in glioblastoma.Neurosurg Clin N Am. 2012 Jul;23(3):379-89. doi: 10.1016/j.nec.2012.04.002. Epub 2012 Jun 5. Neurosurg Clin N Am. 2012. PMID: 22748651 Review.
-
Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.Oncotarget. 2017 Jan 31;8(5):8250-8263. doi: 10.18632/oncotarget.14159. Oncotarget. 2017. PMID: 28030813 Free PMC article.
-
Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.Int J Oncol. 2013 Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23. Int J Oncol. 2013. PMID: 23612755
-
Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment.Cells. 2019 Nov 6;8(11):1398. doi: 10.3390/cells8111398. Cells. 2019. PMID: 31698775 Free PMC article. Review.
-
An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3β/β-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties.Int J Mol Sci. 2021 Feb 28;22(5):2464. doi: 10.3390/ijms22052464. Int J Mol Sci. 2021. PMID: 33671112 Free PMC article.
Cited by
-
Pro-Apoptotic Activity of Epi-Obtusane against Cervical Cancer: Nano Formulation, In Silico Molecular Docking, and Pharmacological Network Analysis.Pharmaceuticals (Basel). 2023 Nov 8;16(11):1578. doi: 10.3390/ph16111578. Pharmaceuticals (Basel). 2023. PMID: 38004443 Free PMC article.
-
Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment.Theranostics. 2021 Sep 27;11(19):9687-9704. doi: 10.7150/thno.60851. eCollection 2021. Theranostics. 2021. PMID: 34646393 Free PMC article.
-
Next Steps for Immunotherapy in Glioblastoma.Cancers (Basel). 2022 Aug 20;14(16):4023. doi: 10.3390/cancers14164023. Cancers (Basel). 2022. PMID: 36011015 Free PMC article. Review.
-
Warburg effect-related risk scoring model to assess clinical significance and immunity characteristics of glioblastoma.Cancer Med. 2023 Nov;12(21):20639-20654. doi: 10.1002/cam4.6627. Epub 2023 Oct 21. Cancer Med. 2023. PMID: 37864422 Free PMC article.
-
RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.Cell Death Dis. 2023 Nov 20;14(11):757. doi: 10.1038/s41419-023-06156-6. Cell Death Dis. 2023. PMID: 37985768 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
